AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, ...

Dr. Mehmet Oz holds millions of dollars worth of shares in health insurance, fertility, pharmaceutical and vitamin companies ...

For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales ... coupled with a long history of innovation, is a big part of what makes AbbVie a blue chip stock and compelling ...

Mehmet Oz, Trump's nominee to lead the Centers for Medicare and Medicaid Services, pledged to divest his investments in ...

Defense Secretary Pete Hegseth has ordered senior military and Defense Department officials to draw up plans to cut 8 percent ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

There are three key reasons to avoid the blue-chip $68 billion SCHD ETF, including better alternatives and lower yield.

AbbVie’s CEO Richard Gonzalez took a huge bet that Rova-T would be the next big thing in oncology. Rova-T had a convincing-looking mechanism of action, consisting of an antibody that locks onto ...

Auto approaches have had the most success of any cell therapies to date, but they’re complicated to administer and come with huge price tags ... cell therapy hits the big leagues.

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

Robert Michael will replace former CEO Richard Gonzalez, marking the official end to Gonzalez’s long reign at the pharma ...